Literature DB >> 9854482

Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis.

A Slominski1, R Paus, M C Mihm.   

Abstract

Melanogenesis generates immunosuppressive and mutagenic environment and alters cellular metabolism. Melanin can protect malignant melanocytes against chemo-, radio-, and photodynamic therapy. Therefore, we propose to inhibit melanogenesis as an adjuvant treatment modality during immuno-, radio-, chemo- and photodynamic therapy, and as a measure of reducing the probability of melanoma progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854482

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  47 in total

1.  Modification of melanogenesis in cultured human melanoma cells.

Authors:  A Slominski; G Ermak; J Wortsman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

2.  Melanoma resistance: a bright future for academicians and a challenge for patient advocates.

Authors:  Andrzej T Slominski; J Andrew Carlson
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 3.  Current position of TNF-α in melanomagenesis.

Authors:  Iuliana Nenu; Diana Tudor; Adriana Gabriela Filip; Ioana Baldea
Journal:  Tumour Biol       Date:  2015-08-18

Review 4.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

5.  The role of constitutively activated STAT3 in B16 melanoma cells.

Authors:  Chuan He Yang; Meiyun Fan; Andrzej T Slominski; Junming Yue; Lawrence M Pfeffer
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2010-01-01

6.  On the relationship between VDR, RORα and RORγ receptors expression and HIF1-α levels in human melanomas.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Anton M Jetten; Andrzej T Slominski
Journal:  Exp Dermatol       Date:  2019-08-08       Impact factor: 3.960

7.  Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Zorica Janjetovic; Andrzej T Slominski
Journal:  Hum Pathol       Date:  2012-09-17       Impact factor: 3.466

8.  On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders.

Authors:  A Slominski
Journal:  Br J Dermatol       Date:  2009-02       Impact factor: 9.302

9.  The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

Authors:  A Slominski; T-K Kim; A A Brożyna; Z Janjetovic; D L P Brooks; L P Schwab; C Skobowiat; W Jóźwicki; T N Seagroves
Journal:  Arch Biochem Biophys       Date:  2014-07-02       Impact factor: 4.013

10.  Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.

Authors:  Andrzej Slominski; Blazej Zbytek; Radomir Slominski
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.